RxDoctor Payments Data

Paul Hiss, MD

Ophthalmology · Sparks, NVNPI 1578522256

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $7,039 of the $9,475 with a category attached, or 74.3%. 16 manufacturers reported payments, led by Heru, Inc. at 56.1% of the total. Reporting peaked in 2022 at $5,662 and has fallen 67.7% since, to $1,831 in 2025.

$9,475in general payments, 2019–2025

Across 77 payments — averaging $123.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heru, Inc.$5K
  • Rxsight Inc$2K
  • Alcon$1K
  • Biotissue Holdings Inc.$231
  • Johnson & Johnson Surgical Vision, Inc.$148
  • Kala Pharmaceuticals, Inc.$147
  • plus $719 from 10 others

What the payments were for

  • Consulting fees$7,03974%
  • Speaking & faculty fees$320%
  • Food & beverage$2,36525%
  • Gifts$390%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,475 in reported general payments places this provider in the 80th percentile of 121 ophthalmology providers in Nevada.

See all ophthalmology providers in Nevada

Medicare billing

Part B allowed, 2024
$301,818
Medicare patients
390
Services billed
1,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast13$12,676
Prednisolone Acetate99$4,802
Ofloxacin96$1,448
Ketorolac Tromethamine26$533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$53$12,67613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 121 ophthalmology providers in Nevada.

Other ophthalmology in Sparks

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →